Avexima has begun construction of a pharmaceutical cluster in the Moscow region for 6.5 billion rubles

A pharmaceutical production and logistics complex with an area of ​​over 170 thousand square meters will be built in the industrial park. It will include a laboratory for developing new drugs, a plant where the company intends to carry out the entire drug production cycle, and a number of other facilities.

The first stage of the complex is planned to be launched in 2027. The entire project will be implemented in 8 years. The enterprise will create over 1.5 thousand jobs. The pharmaceutical cluster intends to produce drugs for the treatment of diseases in the field of cardiology, endocrinology, gastroenterology, gynecology, dermatology, neurology, immunology and oncology.

The company announced the construction of a plant in the Moscow region in November 2017. The investment was then estimated at 4 billion rubles, and there were no details about the project. In February 2021, Avexima determined the parameters of the new plant - the investment volume increased to 5 billion rubles. They wanted to start construction of the facility in the second quarter of 2021, but as a result, the deadlines were shifted for unknown reasons.

In December 2021, the pharmaceutical company signed an agreement with JSC "Moscow Region Development Corporation" to expand cooperation in the construction of a plant in the Yesipovo industrial park. It became known then that the investment amount would increase to 6.5 billion rubles.

According to SPARK-Interfax, Avexima OJSC was registered in 2011 in Moscow and belongs to the Cypriot Avexima ltd. Revenue in 2024 amounted to 5.3 billion rubles, net profit - 8.5 million rubles.

The company owns two factories - Avexima Siberia in the Kemerovo Region and the Irbit Chemical and Pharmaceutical Plant in the Sverdlovsk Region. It also has a production site, Immafarma, in Moscow and a research center based in the Skolkovo Technopark.

The pharmaceutical company's portfolio includes about 120 drug names, including the drug for the treatment of high blood pressure Metoprolol (metoprolol), the antimicrobial agent Nitroxoline (nitroxoline), and the antiviral drug Acyclovir (acyclovir).